Biologic efficacy optimization-a step towards personalized medicine

Rheumatology (United Kingdom)

Volumn 55, Issue 5, 2016, Pages 780-788

  Kiely, Patrick D W ^a  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Biologic therapies; DMARDs; Immunotherapy; Rheumatoid arthritis; Spondyloarthritis; Spondyloarthropathies

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; CLINICAL DECISION MAKING; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; HUMAN; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SEROTYPE; SMOKING; TREATMENT INTERRUPTION;

EID: 84965036066     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev356     Document Type: Review

References (77)

1. Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology (ACR) recommendations for the use of disease-modifying antirheumatic drugs and biologics in the treatment of rheumatoid arthritis (RA). Arthritis Care Res 2012;64:625-39.
2. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
3. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003;144:2195-200.
4. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
5. Sparks C, Moots R, Psarelli E, Huizinga T, Goodson N. Impact of obesity on 1 year outcomes: results from the meteor foundation international rheumatoid arthritis cohort. Arthritis Rheumatol 2014;66(Suppl):1062.
6. Goodman SM, Ma Y, Zhang W et al. Body mass index is an independent risk factor for not achieving sustained remission in early rheumatoid arthritis: results from the CATCH observational study. Ann Rheum Dis 2015;74(Suppl 2):138.2-139.
7. Gremese E, Carletto A, Padovan M et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 2013;65:94-100.
8. Finckh A, Turesson C. The impact of obesity on the development and progression of rheumatoid arthritis. Ann Rheum Dis 2014;73:1911-3.
9. Sparks JA, Halperin F, Karlson JC, Karlson EW, Bermas B. Bariatric surgery improves rheumatoid arthritis disease activity, reduces inflammatory markers, and decreases medication usage. Arthritis Rheumatol 2014;66(Suppl):L17.
10. Gigante MR, Gremese E, Tolusso B et al. Weight loss in obese rheumatoid arthritis patients improves disease activity without modifying RA treatment. Ann Rheum Dis 2015;74(Suppl 2):FRI0021.
11. Nyhall-Wahlin BM, Petersson IF, Nilsson JA, Jacobsson LT, Turesson C the BARFOT study group. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. Rheumatology 2009;48:416-20.
12. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000;27:630-7.
13. Manfredsdottir VF, Vikingsdottir T, Jonsson T et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology 2006;45:734-40.
14. Harrison BJ, Silman AJ, Wiles NJ, Scott DG, Symmons DP. The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum 2001;44:323-30.
15. Saevarsdottir S, Wedrén S, Seddighzadeh M et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011;63:26-36.
16. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-a therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
17. Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM. Anti-TNF-a agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol 2010;16:15-8.
18. Mattey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol 2009;36:1180-7.
19. Khan A, Scott DL, Batley M. Smoking, rheumatoid factor status and responses to rituximab. Ann Rheum Dis 2012;71:1587-8.
20. Chatzidionysiou K, Lie E, Nasonov E et al. Smoking and response to rituximab in anti-CCP positive and negative rheumatoid arthritis-results from an International European Collaboration. Arthritis Rheumatol 2014;66(Suppl):2524.
21. Theander E, Proven A, Fallang A, Svelander L, Trollmo T. Smoking status does not seem to affect tocilizumab efficacy in RA patients. Ann Rheum Dis 2015;74(Suppl 2):FRI0163.
22. Potter C, Hyrich K, Tracey A et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009;68:69-74.
23. Canhão H, Rodrigues AM, Mourão AF et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology 2012;51:2020-6.
24. Connolly S, Maldonado M, Schiff M et al. Modulation of the ACPA fine specificity in patients with RA treated with either abatacept or adalimumab in the AMPLE study. Ann Rheum Dis 2014;73(Suppl 2):395.
25. Lv Q, Yin Y, Li X et al. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFa agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS One 2014;9:e89442.
26. Sellam J, Hendel-Chavez H, Rouanet S et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011;63:933-8.
27. Isaacs J, Olech E, Tak PP et al. Autoantibody-positive rheumatoid arthritis (RA) patients (PTS) have enhanced clinical response to rituximab (RTX) when compared with seronegative patients. Ann Rheum Dis 2009;68(Suppl 3):442.
28. Strangfeld A, Eveslage M, Kekow J et al. Effectiveness of treatment with rituximab depends on autoantibody status- results from 2 years of experience in the German biologics register RABBIT. Arthritis Rheum 2009;60(Suppl):S634-5.
29. Van Vollenhoven RF, Chatzidionysiou K, Nasonov E et al. Characterisation of RA patients not requiring retreatment with rituximab within 12 months after the first course-a CERERRA study. Annals Rheum Dis 2010;68(Suppl 3):FRI0195.
30. Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum 2013;43:9-17.
31. Gottenburg JE, Ravaud P, Cantagrel A et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis 2012;71:1815-9.
32. Gottenburg JE, Neto D, Gomez-Reino J et al. Positivity for rheumatoid factor and anti-cyclic citrullinated peptide is associated with a better drug retention of abatacept: data from a pan-European analysis of RA registries. Ann Rheum Dis 2014;73(Suppl 2):502-3.
33. Nüßlein H, Alten R, Galeazzi M et al. Prognostic factors for IV abatacept retention in patients who have received at least one prior biologic agent: 2-year results from a prospective, international, real-world study. Arthritis Rheumatol 2014;66(Suppl):2491.
34. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
35. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: twoyear clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
36. Burmester G-R, Kivitz AJ, Kupper H et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2014;0:1-8. doi:10.1136/annrheumdis-2013-204769.
37. Lorenz HM, Behrens F, Lippe R et al. Etanercept as monotherapy or in combination with conventional DMARDs in psoriatic arthritis: results from a large prospective multicenter observational study. Ann Rheum Dis 2015;74(Suppl 2):THU0415.
38. Emery P, Burmester G, Bykerk V et al. Induction of clinical remission followed by drug-free withdrawal with abatacept combination and monotherapy in early RA: results from the AVERT study over 18 months. Ann Rheum Dis 2014;73(Suppl 2):69.
39. Edwards JCW, Szczepański L, Szechiński J et al. Efficacy of b-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
40. Dougados M, Kissel K, Sheeran T et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
41. Burmester GR, Rigby W, van Vollenhoven R et al. Tocilizumab in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients with early rheumatoid arthritis: clinical and radiographic outcomes from a randomised, placebo controlled trial. Ann Rheum Dis 2013;72(Suppl 3):A63.
42. Gabay C, Riek M, Hetland M et al. Retention of tocilizumab therapy: a comparison between tocilizumab in monotherapy and in combination with DMARDs based on the TOCERRA collaboration. Ann Rheum Dis 2014;73(Suppl 2):601-2.
43. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
44. Kiely P, Florentinus S, Keidel S et al. Higher likelihood of response in rheumatoid arthritis patients treated in a reallife setting with adalimumab in combination with methotrexate, but not with other DMARDs, versus adalimumab monotherapy. Ann Rheum Dis 2013;72(Suppl 3):A432-3.
45. Chatzidionysiou K, Lie E, Nasonov E et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012;71:374-7.
46. Wendler JSH, Tony H. Effectiveness and safety of rituximab monotherapy compared to rituximab-combination therapy with methotrexate or leflunomide in the German treatment of active rheumatoid arthritis in daily practice trial. Ann Rheum Dis 2009;68(Suppl 3):76.
47. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
48. Jani M, Chinoy H, Warren RB et al. Influence of immunogenicity and drug levels on the efficacy of long-term treatment of rheumatoid arthritis with adalimumab and etanercept: a UK-based prospective study. Ann Rheum Dis 2014;73(Suppl 2):i89-90.
49. Genovese MC, Covarrubias A, Leon G et al. Subcutaneous abatacept versus intravenous abatacept. A phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:2854-64.
50. Burmester GR, Rubbert-Roth A, Cantagrel A et al. A randomized, double blind, parallel-group study of the safety and efficacy of sub cutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease- modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69-74.
51. Maini RN, Breedveld FC, Kalden JR et al. Sustained improvement over two years in physical function, structural damage and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
52. van Schouwenburg PA, van de Stadt LA, de Jong RN et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013;72:104-9.
53. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164-72.
54. Bartelds GM, Krieckaert CLM, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
55. van Schouwenburg PA, Krieckaert CL, Rispens T et al. Long-term measurement of anti-adalimumab using pHshift- anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013;72:1680-6.
56. Braun J, Baraliakos X, Kudrin A, Kim H, Lee SJ. Striking discrepancy in the development of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in response to infliximab (INF) and its biosimilar CT-P13. Arthritis Rheumatol 2014;66(Suppl 10):L21.
57. de Vries MK, Wolbink GJ, Stapel SO et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252-4.
58. Krieckaert C, Vogelzang E, Pouw M, Nurmohamed M, Wolbink G. Adalimumab serum concentrations in patients with rheumatoid arthritis or psoriatic arthritis taking concomitant DMARD therapy. Ann Rheum Dis 2014;73(Suppl 2):OP0252.
59. van Kuijk AW, van Kuijk AWR, de Groot M et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010;69:624-5.
60. Vogelzang E, Kneepkens E, Nurmohamed M et al. A concentration-effect curve of adalimumab in patients with psoriatic arthritis. Ann Rheum Dis 2014;73(Suppl 2):88-9.
61. Rosas J, Llinares-Tello F, Senabre-Gallego JM et al. Cutoff level of adalimumab and prevalence of antibodies antiadalimumab in patients with ankylosing spondylitis: results from a local registry. Arthritis Rheumatol 2014;66(Suppl 10):1531.
62. Plasencia C, Kneepkens E, Krieckaert C et al. The influence of golimumab levels on clinical response in spondyloarthritis patients at 52 weeks of follow-up. Ann Rheum Dis 2014;73(Suppl 2):712-3.
63. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947-55.
64. Jamnitski A, Krieckaert CL, Nurmohamed MT et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71:88-91.
65. Daïen CI, Daïen V, Parussini E et al. Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study. J Rheumatol 2012;39:1533-8.
66. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Antiinfliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and antitumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21.
67. Jamnitski A, Bartelds GM, Nurmohamed MT et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to Etanercept. Ann Rheum Dis 2011;70:284-8.
68. Smolen JS, Aletaha D, Bijlsma JWJ et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
69. Kavanaugh A, Klareskog L, van der Heijde D et al. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis 2008;67:1444-7.
70. Dougados M, Keystone EC, Guerette B, Patra K, Lavie F. How early can we predict remission at 1 year in early rheumatoid arthritis? A subanalysis of PREMIER. Arthritis Rheum 2009;60(Suppl 10):1607.
71. van der Heijde D, Keystone EC, Curtis JR et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 Trial. J Rheumatol 2012;39:1326-33.
72. Emery P, Spieler W, Stopinska-Polaszewska M et al. Assessing maintenance of remission after withdrawal of etanercept plus methotrexate, methotrexate alone, or placebo in early rheumatoid arthritis patients who achieved remission with etanercept and methotrexate. The Prize study. Arthritis Rheum 2013;65(Suppl 10):2689.
73. Henaux S, Barnetche T, Ruyssen Witrand A et al. Treatment adjustment strategy after achieving remission or low disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Rheumatol 2014;66(Suppl 10):2483.
74. van Kuijk AWR, de Groot M, Stapel SO et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010;69:624-5.
75. Pouw MF, Krieckaert CL, Nurmohamed MT et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2015;74:513-8.
76. van Herwaarden N, Bouman C, van der Maas A et al. Prediction of successful dose reduction or discontinuation of adalimumab or etanercept using serum drug levels and antidrug antibody measurement. Arthritis Rheumatol 2014;66(Suppl 10):500.
77. Krieckaert CLM, Nair SC, Nurmohamed MT et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis 2015;74:361-8.